Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Otitis Media - Overview
Otitis Media - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Otitis Media - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Otitis Media - Companies Involved in Therapeutics Development
Blue Water Vaccines Inc
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earno LLC
Furen Pharmaceutical Group Co Ltd
Hun Sanqing Pharmaceutical Co Ltd
Inventprise LLC
Laboratorios Salvat SA
Maxwell Biosciences Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc
Otitis Media - Drug Profiles
(ciprofloxacin hydrochloride + fluocinolone acetonide) - Drug Profile
Product Description
Mechanism Of Action
History of Events
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
BWV-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMTX-200 - Drug Profile
Product Description
Mechanism Of Action
CMTX-301 - Drug Profile
Product Description
Mechanism Of Action
Drug for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
Drugs for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
ENT-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fifloxacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
IVT-25 - Drug Profile
Product Description
Mechanism Of Action
NTC-011 - Drug Profile
Product Description
Mechanism Of Action
OR-404IT - Drug Profile
Product Description
Mechanism Of Action
History of Events
PCL-1440 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal polysaccharide [15-valent] vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Chronic Suppurative Otitis Media (CSOM) - Drug Profile
Product Description
Mechanism Of Action
History of Events
solithromycin - Drug Profile
Product Description
Mechanism Of Action
History of Events
tebipenem pivoxil - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
VAX-24 - Drug Profile
Product Description
Mechanism Of Action
VAX-XP - Drug Profile
Product Description
Mechanism Of Action
VT-1917 - Drug Profile
Product Description
Mechanism Of Action
Otitis Media - Dormant Projects
Otitis Media - Discontinued Products
Otitis Media - Product Development Milestones
Featured News & Press Releases
Dec 20, 2021: Clarametyx Biosciences awarded $3.15 million grant from NIH to advance a broad-spectrum vaccine technology for bacterial infections
Oct 04, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement - Update on the commercialisation and research and development of Cetraxal Plus of the group
Sep 01, 2021: noCarrier : Accomplishment of primary endpoint in phase III clinical study of ENT103
May 31, 2021: noCarrier : Completion of patient enrollment for phase III trial with ENT103
Jan 13, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement update on an investigatiol ear drug product
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
May 18, 2017: Pediapharm Announces the Commercial Launch of Otixal in Cada
Dec 27, 2016: OTOVEL’s trials published in JAMA
Dec 12, 2016: Pediapharm receives Health Cada approval for Otixal
Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combition solution in the treatment of AOMT with Tympanostomy tubes
May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combition In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes
Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Fifloxacin For Treatment Of Acute Otitis Media
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Otitis Media, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Otitis Media, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Otitis Media - Pipeline by Blue Water Vaccines Inc, 2022
Otitis Media - Pipeline by Ceolia Pharma Co Ltd, 2022
Otitis Media - Pipeline by Clarametyx Biosciences Inc, 2022
Otitis Media - Pipeline by Earnano LLC, 2022
Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd, 2022
Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2022
Otitis Media - Pipeline by Inventprise LLC, 2022
Otitis Media - Pipeline by Laboratorios Salvat SA, 2022
Otitis Media - Pipeline by Maxwell Biosciences Inc, 2022
Otitis Media - Pipeline by Merck & Co Inc, 2022
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022
Otitis Media - Pipeline by MyX Therapeutics Inc, 2022
Otitis Media - Pipeline by NTC srl, 2022
Otitis Media - Pipeline by O-Ray Pharma Inc, 2022
Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, 2022
Otitis Media - Pipeline by ProclaRx LLC, 2022
Otitis Media - Pipeline by Vaxcyte Inc, 2022
Otitis Media - Pipeline by Vyome Therapeutics Inc, 2022
Otitis Media - Dormant Projects, 2022
Otitis Media - Discontinued Products, 2022